UHC Medicare Certification Independent Practice
Questions & Answers | Comprehensive
UnitedHealthcare Medicare Training & Exam
Preparation Study Guide | Medicare Advantage (MA),
Medicare Part D, Eligibility & Enrollment, Plan
Benefits, Member Rights, Compliance, Agent
Training, Privacy, Communication Standards,
Regulatory Concepts & Detailed Rationales
Question 1: A Medicare beneficiary is enrolled in a Medicare Advantage (MA)
plan and is approaching the end of their Initial Coverage Period (ICP) for Part
D. They have a True Out-of-Pocket (TrOOP) threshold that has not yet been
met. Which of the following accurately describes the financial responsibility
for a brand-name drug that is on the plan's formulary once the beneficiary
enters the Coverage Gap (Donut Hole)?
A. The beneficiary pays 25% of the negotiated price for the brand-name drug, and the
manufacturer's discount does not apply to the generic portion.
B. The beneficiary pays 25% of the negotiated price for the brand-name drug, and 70%
of the manufacturer's discount counts towards TrOOP.
C. The beneficiary pays 25% of the negotiated price for the brand-name drug, and 80%
of the manufacturer's discount counts towards TrOOP.
D. The beneficiary pays 100% of the negotiated price for the brand-name drug until they
reach the Catastrophic Coverage phase.
CORRECT ANSWER: B. The beneficiary pays 25% of the negotiated price for
the brand-name drug, and 70% of the manufacturer's discount counts towards
TrOOP.
Rationale: Under the Inflation Reduction Act, for brand-name drugs in the Coverage
Gap, the beneficiary's cost-sharing is 25% of the negotiated price. The manufacturer
provides a 70% discount, and this discount counts toward the beneficiary's TrOOP
(True Out-of-Pocket) costs. The plan covers the remaining 5%. Option A is incorrect
because the manufacturer discount does apply; Option C is incorrect because 80% is the
correct percentage for coverage of generic drugs in the gap, not the discount counting
towards TrOOP; Option D is incorrect because the beneficiary does not pay 100% in the
gap.
Question 2: A Medicare beneficiary is considering enrolling in a Medicare
Supplement (Medigap) policy. They are currently 66 years old and have been
enrolled in Medicare Part B for 7 months. They are concerned about coverage
for foreign travel emergencies. Which of the following statements is true
regarding Medigap and foreign travel?
A. All Medigap policies are required to cover foreign travel emergencies at 80% of the
cost after a $250 deductible.
B. Only Medigap Plans C, D, F, G, M, and N offer foreign travel emergency coverage, and
it is typically limited to 80% coverage after a $250 deductible.
,C. No Medigap policy covers foreign travel emergencies, as Medicare does not cover
these services.
D. Foreign travel emergency coverage is available in all Medigap plans but only if the
beneficiary has had the policy for more than 12 months.
CORRECT ANSWER: B. Only Medigap Plans C, D, F, G, M, and N offer foreign
travel emergency coverage, and it is typically limited to 80% coverage after a
$250 deductible.
Rationale: Medigap foreign travel emergency coverage is standardized. Plans C, D, F,
G, M, and N include this benefit. The benefit covers 80% of the cost of medically
necessary emergency care outside the U.S. after the beneficiary meets a $250
deductible, with a lifetime maximum benefit of $50,000. Option A is incorrect because
not all plans are required to offer it; Option C is incorrect because some Medigap
policies do offer it; Option D is incorrect because it is not offered in all plans, and the 12-
month rule is not a standard requirement.
Question 3: An employer with 30 employees offers a group health plan. The
employer is considering dropping its prescription drug coverage and wants to
notify Medicare beneficiaries that their coverage is "creditable." What is the
primary requirement for determining if the group plan's prescription drug
coverage is creditable?
A. The coverage must be at least as good as the standard Medicare Part D coverage,
meaning it has an actuarial value equal to or exceeding Medicare's standard Part D
coverage.
B. The coverage must have no annual deductible and a flat $5 copay for all generics.
C. The coverage must cover at least 50% of all brand-name prescription drugs on the
market.
D. The coverage must be provided by a licensed insurance carrier that is accredited by
the National Committee for Quality Assurance (NCQA).
CORRECT ANSWER: A. The coverage must be at least as good as the standard
Medicare Part D coverage, meaning it has an actuarial value equal to or
exceeding Medicare's standard Part D coverage.
Rationale: Creditable coverage is defined by CMS as coverage that is expected to pay,
on average, as much as the standard Medicare Part D prescription drug coverage. This is
an actuarial determination. It is not based on a specific deductible amount, a percentage
of all brand-name drugs, or the carrier's accreditation status. Option B is incorrect
because it describes a plan design that is not the standard; Option C is incorrect
because coverage is not measured by a percentage of all brand-name drugs; Option D is
incorrect because NCQA accreditation is not a requirement for creditability.
Question 4: A Medicare beneficiary has a Medicare Advantage (MA) plan with
a $0 premium and a $250 deductible for in-network services. The beneficiary is
hospitalized for 5 days. The plan's daily copay for days 1-5 is $350. Which of
,the following is the maximum out-of-pocket (MOOP) limit for Medicare
Advantage plans in 2026?
A. There is no MOOP limit for Medicare Advantage plans, only for Medigap.
B. The MOOP limit for in-network services is $9,350 and for out-of-network is $14,000.
C. The MOOP limit for in-network services is $8,850 and for out-of-network is $13,300.
D. The MOOP limit for all services combined (in and out of network) is a single amount
of $12,450.
CORRECT ANSWER: C. The MOOP limit for in-network services is $8,850 and
for out-of-network is $13,300.
Rationale: For 2026, CMS has set the Medicare Advantage MOOP limits. The in-
network MOOP is $8,850, and the out-of-network MOOP is $13,300. Option A is
incorrect because MOOP limits do exist for MA plans. Option B is incorrect as these are
the 2025 amounts. Option D is incorrect because the MOOP is not a single combined
amount; there are separate limits for in-network and out-of-network.
Question 5: A 65-year-old beneficiary is new to Medicare and is looking at a
Medicare Advantage (MA) plan that offers a Part D drug benefit. The plan has
a $0 deductible for all tiers. Which of the following statements best describes
the Initial Coverage Period (ICP) for Part D under this plan?
A. The ICP begins after the beneficiary has spent $2,000 in TrOOP.
B. The ICP begins immediately with the first prescription fill, and the beneficiary pays a
defined copay or coinsurance until their total drug costs reach $2,000.
C. The ICP begins after the deductible is met, which in this case is $0, and continues
until the beneficiary's total drug costs reach the Out-of-Pocket Threshold of $8,000.
D. The ICP begins immediately, but only for generic drugs; brand-name drugs are
subject to a separate deductible.
CORRECT ANSWER: C. The ICP begins after the deductible is met, which in
this case is $0, and continues until the beneficiary's total drug costs reach the
Out-of-Pocket Threshold of $8,000.
Rationale: The Initial Coverage Period (ICP) begins after the deductible is met. Since
the plan has a $0 deductible, the ICP starts with the first fill. The ICP continues until the
beneficiary's total drug costs reach the Out-of-Pocket Threshold (which is $8,000 for
2026, including TrOOP and manufacturer discounts). Option A is incorrect because the
$2,000 threshold is the new cap on out-of-pocket spending, not the beginning of the ICP.
Option B is incorrect because it states the ICP continues until total drug costs reach
$2,000, which is the out-of-pocket cap, not the end of the ICP. Option D is incorrect
because the ICP applies to both generic and brand-name drugs.
Question 6: A Medicare beneficiary is deciding between a Medicare Advantage
(MA) plan and a Medigap policy. They are currently healthy but want to
understand their rights if they develop a chronic condition. Under federal law,
which of the following is true regarding guaranteed issue rights for Medigap?
, A. Guaranteed issue rights for Medigap are available to all beneficiaries during their
initial enrollment period and during certain qualifying events, such as losing employer
coverage.
B. Guaranteed issue rights for Medigap are available at any time, regardless of health
status, as long as the beneficiary pays a higher premium.
C. Guaranteed issue rights for Medigap are only available during the beneficiary's 65th
birthday month.
D. Guaranteed issue rights for Medigap are not available to beneficiaries who choose a
Medicare Advantage plan for the first time.
CORRECT ANSWER: A. Guaranteed issue rights for Medigap are available to all
beneficiaries during their initial enrollment period and during certain
qualifying events, such as losing employer coverage.
Rationale: Guaranteed issue rights mean the insurance company cannot deny
coverage, impose a waiting period, or charge a higher premium based on health status.
These rights apply during the Medigap Open Enrollment Period (the 6-month period
starting the first month the beneficiary is 65 or older and enrolled in Part B) and during
specific qualifying events, such as losing employer-sponsored coverage. Option B is
incorrect because guaranteed issue rights are not available at all times; they are limited
to specific periods. Option C is incorrect because the period is 6 months, not just the
birthday month. Option D is incorrect because beneficiaries who leave an MA plan
during their first 12 months of enrollment have guaranteed issue rights for Medigap.
Question 7: A Medicare beneficiary has a Medicare Advantage (MA) plan that
requires prior authorization for a specific brand-name medication. The
beneficiary's provider submits a prior authorization request, and it is denied.
The beneficiary wants to appeal the decision. What is the first step in the
Medicare Advantage appeal process?
A. File a complaint with the state insurance commissioner.
B. Request a reconsideration (Redetermination) from the MA plan.
C. Request a hearing before an Administrative Law Judge (ALJ).
D. File a grievance with the MA plan.
CORRECT ANSWER: B. Request a reconsideration (Redetermination) from the
MA plan.
Rationale: The Medicare Advantage appeal process has five levels. The first level is a
Redetermination by the plan. The beneficiary must file this appeal within 60 days of the
denial notice. Option A is incorrect because the insurance commissioner is not the first
step; the state department of insurance may be involved later, but the plan-level appeal
is first. Option C is incorrect because an ALJ hearing is the third level of appeal. Option
D is incorrect because a grievance is for complaints about the quality of care or service,
not for coverage denials.
Questions & Answers | Comprehensive
UnitedHealthcare Medicare Training & Exam
Preparation Study Guide | Medicare Advantage (MA),
Medicare Part D, Eligibility & Enrollment, Plan
Benefits, Member Rights, Compliance, Agent
Training, Privacy, Communication Standards,
Regulatory Concepts & Detailed Rationales
Question 1: A Medicare beneficiary is enrolled in a Medicare Advantage (MA)
plan and is approaching the end of their Initial Coverage Period (ICP) for Part
D. They have a True Out-of-Pocket (TrOOP) threshold that has not yet been
met. Which of the following accurately describes the financial responsibility
for a brand-name drug that is on the plan's formulary once the beneficiary
enters the Coverage Gap (Donut Hole)?
A. The beneficiary pays 25% of the negotiated price for the brand-name drug, and the
manufacturer's discount does not apply to the generic portion.
B. The beneficiary pays 25% of the negotiated price for the brand-name drug, and 70%
of the manufacturer's discount counts towards TrOOP.
C. The beneficiary pays 25% of the negotiated price for the brand-name drug, and 80%
of the manufacturer's discount counts towards TrOOP.
D. The beneficiary pays 100% of the negotiated price for the brand-name drug until they
reach the Catastrophic Coverage phase.
CORRECT ANSWER: B. The beneficiary pays 25% of the negotiated price for
the brand-name drug, and 70% of the manufacturer's discount counts towards
TrOOP.
Rationale: Under the Inflation Reduction Act, for brand-name drugs in the Coverage
Gap, the beneficiary's cost-sharing is 25% of the negotiated price. The manufacturer
provides a 70% discount, and this discount counts toward the beneficiary's TrOOP
(True Out-of-Pocket) costs. The plan covers the remaining 5%. Option A is incorrect
because the manufacturer discount does apply; Option C is incorrect because 80% is the
correct percentage for coverage of generic drugs in the gap, not the discount counting
towards TrOOP; Option D is incorrect because the beneficiary does not pay 100% in the
gap.
Question 2: A Medicare beneficiary is considering enrolling in a Medicare
Supplement (Medigap) policy. They are currently 66 years old and have been
enrolled in Medicare Part B for 7 months. They are concerned about coverage
for foreign travel emergencies. Which of the following statements is true
regarding Medigap and foreign travel?
A. All Medigap policies are required to cover foreign travel emergencies at 80% of the
cost after a $250 deductible.
B. Only Medigap Plans C, D, F, G, M, and N offer foreign travel emergency coverage, and
it is typically limited to 80% coverage after a $250 deductible.
,C. No Medigap policy covers foreign travel emergencies, as Medicare does not cover
these services.
D. Foreign travel emergency coverage is available in all Medigap plans but only if the
beneficiary has had the policy for more than 12 months.
CORRECT ANSWER: B. Only Medigap Plans C, D, F, G, M, and N offer foreign
travel emergency coverage, and it is typically limited to 80% coverage after a
$250 deductible.
Rationale: Medigap foreign travel emergency coverage is standardized. Plans C, D, F,
G, M, and N include this benefit. The benefit covers 80% of the cost of medically
necessary emergency care outside the U.S. after the beneficiary meets a $250
deductible, with a lifetime maximum benefit of $50,000. Option A is incorrect because
not all plans are required to offer it; Option C is incorrect because some Medigap
policies do offer it; Option D is incorrect because it is not offered in all plans, and the 12-
month rule is not a standard requirement.
Question 3: An employer with 30 employees offers a group health plan. The
employer is considering dropping its prescription drug coverage and wants to
notify Medicare beneficiaries that their coverage is "creditable." What is the
primary requirement for determining if the group plan's prescription drug
coverage is creditable?
A. The coverage must be at least as good as the standard Medicare Part D coverage,
meaning it has an actuarial value equal to or exceeding Medicare's standard Part D
coverage.
B. The coverage must have no annual deductible and a flat $5 copay for all generics.
C. The coverage must cover at least 50% of all brand-name prescription drugs on the
market.
D. The coverage must be provided by a licensed insurance carrier that is accredited by
the National Committee for Quality Assurance (NCQA).
CORRECT ANSWER: A. The coverage must be at least as good as the standard
Medicare Part D coverage, meaning it has an actuarial value equal to or
exceeding Medicare's standard Part D coverage.
Rationale: Creditable coverage is defined by CMS as coverage that is expected to pay,
on average, as much as the standard Medicare Part D prescription drug coverage. This is
an actuarial determination. It is not based on a specific deductible amount, a percentage
of all brand-name drugs, or the carrier's accreditation status. Option B is incorrect
because it describes a plan design that is not the standard; Option C is incorrect
because coverage is not measured by a percentage of all brand-name drugs; Option D is
incorrect because NCQA accreditation is not a requirement for creditability.
Question 4: A Medicare beneficiary has a Medicare Advantage (MA) plan with
a $0 premium and a $250 deductible for in-network services. The beneficiary is
hospitalized for 5 days. The plan's daily copay for days 1-5 is $350. Which of
,the following is the maximum out-of-pocket (MOOP) limit for Medicare
Advantage plans in 2026?
A. There is no MOOP limit for Medicare Advantage plans, only for Medigap.
B. The MOOP limit for in-network services is $9,350 and for out-of-network is $14,000.
C. The MOOP limit for in-network services is $8,850 and for out-of-network is $13,300.
D. The MOOP limit for all services combined (in and out of network) is a single amount
of $12,450.
CORRECT ANSWER: C. The MOOP limit for in-network services is $8,850 and
for out-of-network is $13,300.
Rationale: For 2026, CMS has set the Medicare Advantage MOOP limits. The in-
network MOOP is $8,850, and the out-of-network MOOP is $13,300. Option A is
incorrect because MOOP limits do exist for MA plans. Option B is incorrect as these are
the 2025 amounts. Option D is incorrect because the MOOP is not a single combined
amount; there are separate limits for in-network and out-of-network.
Question 5: A 65-year-old beneficiary is new to Medicare and is looking at a
Medicare Advantage (MA) plan that offers a Part D drug benefit. The plan has
a $0 deductible for all tiers. Which of the following statements best describes
the Initial Coverage Period (ICP) for Part D under this plan?
A. The ICP begins after the beneficiary has spent $2,000 in TrOOP.
B. The ICP begins immediately with the first prescription fill, and the beneficiary pays a
defined copay or coinsurance until their total drug costs reach $2,000.
C. The ICP begins after the deductible is met, which in this case is $0, and continues
until the beneficiary's total drug costs reach the Out-of-Pocket Threshold of $8,000.
D. The ICP begins immediately, but only for generic drugs; brand-name drugs are
subject to a separate deductible.
CORRECT ANSWER: C. The ICP begins after the deductible is met, which in
this case is $0, and continues until the beneficiary's total drug costs reach the
Out-of-Pocket Threshold of $8,000.
Rationale: The Initial Coverage Period (ICP) begins after the deductible is met. Since
the plan has a $0 deductible, the ICP starts with the first fill. The ICP continues until the
beneficiary's total drug costs reach the Out-of-Pocket Threshold (which is $8,000 for
2026, including TrOOP and manufacturer discounts). Option A is incorrect because the
$2,000 threshold is the new cap on out-of-pocket spending, not the beginning of the ICP.
Option B is incorrect because it states the ICP continues until total drug costs reach
$2,000, which is the out-of-pocket cap, not the end of the ICP. Option D is incorrect
because the ICP applies to both generic and brand-name drugs.
Question 6: A Medicare beneficiary is deciding between a Medicare Advantage
(MA) plan and a Medigap policy. They are currently healthy but want to
understand their rights if they develop a chronic condition. Under federal law,
which of the following is true regarding guaranteed issue rights for Medigap?
, A. Guaranteed issue rights for Medigap are available to all beneficiaries during their
initial enrollment period and during certain qualifying events, such as losing employer
coverage.
B. Guaranteed issue rights for Medigap are available at any time, regardless of health
status, as long as the beneficiary pays a higher premium.
C. Guaranteed issue rights for Medigap are only available during the beneficiary's 65th
birthday month.
D. Guaranteed issue rights for Medigap are not available to beneficiaries who choose a
Medicare Advantage plan for the first time.
CORRECT ANSWER: A. Guaranteed issue rights for Medigap are available to all
beneficiaries during their initial enrollment period and during certain
qualifying events, such as losing employer coverage.
Rationale: Guaranteed issue rights mean the insurance company cannot deny
coverage, impose a waiting period, or charge a higher premium based on health status.
These rights apply during the Medigap Open Enrollment Period (the 6-month period
starting the first month the beneficiary is 65 or older and enrolled in Part B) and during
specific qualifying events, such as losing employer-sponsored coverage. Option B is
incorrect because guaranteed issue rights are not available at all times; they are limited
to specific periods. Option C is incorrect because the period is 6 months, not just the
birthday month. Option D is incorrect because beneficiaries who leave an MA plan
during their first 12 months of enrollment have guaranteed issue rights for Medigap.
Question 7: A Medicare beneficiary has a Medicare Advantage (MA) plan that
requires prior authorization for a specific brand-name medication. The
beneficiary's provider submits a prior authorization request, and it is denied.
The beneficiary wants to appeal the decision. What is the first step in the
Medicare Advantage appeal process?
A. File a complaint with the state insurance commissioner.
B. Request a reconsideration (Redetermination) from the MA plan.
C. Request a hearing before an Administrative Law Judge (ALJ).
D. File a grievance with the MA plan.
CORRECT ANSWER: B. Request a reconsideration (Redetermination) from the
MA plan.
Rationale: The Medicare Advantage appeal process has five levels. The first level is a
Redetermination by the plan. The beneficiary must file this appeal within 60 days of the
denial notice. Option A is incorrect because the insurance commissioner is not the first
step; the state department of insurance may be involved later, but the plan-level appeal
is first. Option C is incorrect because an ALJ hearing is the third level of appeal. Option
D is incorrect because a grievance is for complaints about the quality of care or service,
not for coverage denials.
